Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Neuroendocrine Tumor
95%
Stomach Adenocarcinoma
88%
Cancer
70%
Neoplasm
55%
Abdominal Cancer
51%
Immunotherapy
50%
Adenocarcinoma
50%
Nivolumab
47%
Malignant Neoplasm
34%
Overall Survival
32%
Gamma Urogastrone
31%
Epidermal Growth Factor Receptor 2
31%
Targeted Therapy
30%
Gastroesophageal Junction
30%
Diseases
29%
Biological Marker
29%
Surgery
26%
Esophageal Squamous Cell Carcinoma
23%
Chemoradiotherapy
22%
Metastatic Carcinoma
22%
Treatment Response
19%
Arm
19%
Combination Therapy
18%
Peritoneum Metastasis
18%
Acinic Cell Carcinoma
15%
Gastrointestinal Tract
15%
Dedifferentiated Liposarcoma
15%
Fusobacterium nucleatum
15%
Uterine Cancer
15%
Cancer of Unknown Primary Origin
15%
Abdominal Wall
15%
Clear Cell Renal Cell Carcinoma
15%
Atezolizumab
15%
Capillary Hemangioma
15%
Programmed Death 1 Ligand 1
15%
Genitourinary System
15%
Well Differentiated Liposarcoma
15%
Pyogenic Granuloma
15%
Granuloma
15%
Diagnosis
15%
Standardized Uptake Value
15%
Esophageal Cancer
15%
Ferroptosis
15%
Disease Exacerbation
15%
Gastrointestinal Carcinoma
15%
Ascites Cell
15%
Carcinomatous Peritonitis
15%
Tumor Microenvironment
12%
Neuroendocrine Carcinoma
11%
Urinary System
10%
Keyphrases
Gastric Adenocarcinoma
100%
Neuroendocrine Neoplasms
87%
Nivolumab
47%
Adenocarcinoma of the Esophagogastric Junction
41%
Tumor
39%
Chemotherapy
32%
Human Epidermal Growth Factor Receptor 2 (HER2)
31%
Gastroesophageal Adenocarcinoma
31%
Neuroendocrine Tumor
31%
Gastroesophageal Cancer
31%
Peritoneal Carcinomatosis
30%
Overall Survival
26%
Gastric Cancer
25%
Yes-associated Protein 1 (YAP1)
24%
Neoadjuvant
23%
Surgical Resection
23%
Targeted Therapy
22%
Pathological Complete Response
21%
Esophageal Squamous Cell Carcinoma
21%
Advanced or Metastatic
21%
Esophageal Adenocarcinoma
21%
Small Intestine
19%
Locally Advanced
19%
Single-arm Study
19%
Programmed Death-ligand 1 (PD-L1)
19%
Ascites
18%
Esophageal Cancer
17%
Image Features
17%
MD Anderson Cancer Center
17%
Gastrointestinal Tract
17%
Emerging Therapeutics
17%
Advanced Stage
16%
Genomic Profiling
15%
Post-resection
15%
Claudin-18
15%
Without Chemotherapy
15%
Slow-growing
15%
Therapy Response
15%
SMARCA4 Gene
15%
Urinary System
15%
Diffuse-type Gastric Adenocarcinoma
15%
Combination Therapy
15%
Diagnostic Approach
15%
Appendiceal Neuroendocrine Neoplasms
15%
Risk Stratification
15%
Atypical Lipomatous Tumor
15%
Appendiceal
15%
Microsatellite Status
15%
FIGO Staging System
15%
CLDN18.2
15%
